中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2014年
11期
24-24,25
,共2页
左卡尼汀%缺血性心肌病%心力衰竭%应用效果
左卡尼汀%缺血性心肌病%心力衰竭%應用效果
좌잡니정%결혈성심기병%심력쇠갈%응용효과
l-carnitine%Ischemic cardiomyopathy. Heart failure%Application effect
目的：探讨在缺血性心肌病心力衰竭患者中对左卡尼汀进行应用的临床效果。方法：对2011～2013年我院收治的64例缺血性心肌病心力衰竭患者进行随机数字表法分组，每组各32例，将其中实施抗血小板聚集、抗心肌缺血、利尿剂及血管紧张素转移酶抑制剂等常规治疗者设为对照组，将在此前提下施加左卡尼汀治疗者设为观察组，评估两组的治疗结局，总结治疗经验。结果：观察组经治疗后，可取得93.8%的临床疗效，较之对照组的68.8%，差异明显（P＜0.05）。治疗后，观察组在左室射血分数（LVEF）、左室舒张末内径（LVEDD）及心输出量（CO）等心脏超声指标方面要较之治疗前、对照组有显著性改善（P＜0.05）。结论：为缺血性心肌病心力衰竭患者提供左卡尼汀进行治疗，能够保障临床疗效，帮助患者改善病情，是今后临床提高本病治疗水平的关键，建议普及。
目的：探討在缺血性心肌病心力衰竭患者中對左卡尼汀進行應用的臨床效果。方法：對2011～2013年我院收治的64例缺血性心肌病心力衰竭患者進行隨機數字錶法分組，每組各32例，將其中實施抗血小闆聚集、抗心肌缺血、利尿劑及血管緊張素轉移酶抑製劑等常規治療者設為對照組，將在此前提下施加左卡尼汀治療者設為觀察組，評估兩組的治療結跼，總結治療經驗。結果：觀察組經治療後，可取得93.8%的臨床療效，較之對照組的68.8%，差異明顯（P＜0.05）。治療後，觀察組在左室射血分數（LVEF）、左室舒張末內徑（LVEDD）及心輸齣量（CO）等心髒超聲指標方麵要較之治療前、對照組有顯著性改善（P＜0.05）。結論：為缺血性心肌病心力衰竭患者提供左卡尼汀進行治療，能夠保障臨床療效，幫助患者改善病情，是今後臨床提高本病治療水平的關鍵，建議普及。
목적：탐토재결혈성심기병심력쇠갈환자중대좌잡니정진행응용적림상효과。방법：대2011～2013년아원수치적64례결혈성심기병심력쇠갈환자진행수궤수자표법분조，매조각32례，장기중실시항혈소판취집、항심기결혈、이뇨제급혈관긴장소전이매억제제등상규치료자설위대조조，장재차전제하시가좌잡니정치료자설위관찰조，평고량조적치료결국，총결치료경험。결과：관찰조경치료후，가취득93.8%적림상료효，교지대조조적68.8%，차이명현（P＜0.05）。치료후，관찰조재좌실사혈분수（LVEF）、좌실서장말내경（LVEDD）급심수출량（CO）등심장초성지표방면요교지치료전、대조조유현저성개선（P＜0.05）。결론：위결혈성심기병심력쇠갈환자제공좌잡니정진행치료，능구보장림상료효，방조환자개선병정，시금후림상제고본병치료수평적관건，건의보급。
Objective: to study the in patients with ischemic cardiomyopathy heart failure for application of the clinical effect of l-carnitine. Methods: 2011 cases in our hospital from 2011 to 2013 in patients with ischemic cardiomyopathy heart failure with random number table method group, 32 cases in each group, wil be the implementation of anti platelet aggregation, against myocardial ischemia, diuretic and angiotensin transferase inhibitors such as routine treatment as control group, would impose l-carnitine treatment under the premise set as observation group, assess the treatment outcome of the two groups, summarize the treatment experience. Results: the observation group after treatment, the clinical efficacy of 93.8%can be obtained, compared with 68.8% in the control group, significant difference (P < 0.05). After treatment, the observation group in the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and cardiac output (CO), cardiac ultrasound indicators compared with before treatment, control group improved significantly (P < 0.05). Conclusion: l-carnitine for patients with ischemic cardiomyopathy heart failure treatment, can guarantee the clinical curative effect, help improve patient, is the key to future clinical improve the level of the disease treatment, advice.
